Sublingual specific immunotherapy, efficacy, safety, immune mechanisms - Current knowledge;Skuteczność, bezpieczeństwo i mechanizmy działania podjȩzykowej immunoterapii alergenowej - Aktualny stan wiedzy

Pediatria Polska

Volumn 82, Issue 8, 2007, Pages 635-641

  Kaczmarek, Joanna ^a   Stelmach, Iwona ^a,b  

^a Oddzia Kliniczny Interny Dzieciecej I Alergologii III Katedry Pediatrii Uniw Medycznego W Lodzi   (Poland)

^b M Kopernik Hospital   (Poland)

Author keywords

Efficacy; Immune mechanisms; Safety; Specific sublingual immunotherapy

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT;

CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; PRICK TEST; RESPIRATORY FUNCTION; REVIEW;

EID: 34547811412     PISSN: 00313939     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0031-3939(07)70357-8     Document Type: Review

References (70)

1. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997; 8: 21-27.
2. Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Galvain S, i wsp. Sublingual-swallow immunotherapy with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999; 54: 8193828.
3. Yuksel H, Tanac R, Gousseinov A, Demir E. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. J Investig Allergol Clin Immunol 1999; 9: 305-313.
4. Piazza I, Bizzaro N. Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermato phagoides pteronyssinus. Ann Allergy 1993; 71: 461-469.
5. Quirino T, Iemoli E, Siciliani E, Parciani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996; 26: 1253-1261.
6. Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma - a placebo controlled. Ann Allergy Asthma Immunol 1999; 82: 485-490.
7. Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F. Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005; 60: 952-956.
8. Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual-swallow immunotherapy in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000; 55: 369-575.
9. Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacobson M, i wsp. Grass pollen sublingual immunotherapy for seasonal rhinocojunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32: 507-514.
10. Nelken D. Sublingual immunotherapy. Harefuah 1996; 131: 164-165.
11. Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2006; 97: 158-163.
12. Hordijk GJ, Antvelink JB, Luwema RA. Sublingual immunotherapy with a standardized grass pollen extract; a double-blind placebo-controlled study. Allergol Immunopathol 1998; 26: 234-240.
13. La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract In children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104: 425-432.
14. Vourdas D, Syrigou E, Poamianou P, Carat F, Batard T, Andre C, i wsp. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinocojunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998; 53: 662-672.
15. Cistero Bahima A, Sastre J, Enrique E, Fernandez M, Alonso R, Quirce S, i wsp. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Invest Allergol Clin Immunol 2004; 14: 17-25.
16. Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35: 565-571.
17. Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, i wsp. Safety of sublingual-swallow immunotherapy In children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005; 95: 254-258.
18. Bahceciler NN, Arikan C, Taylor A, Akids M, Blaser K, Barlan IB, i wsp. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136: 287-294.
19. Rodriguez F, Boquete M, Ibanez MD, de la Torre-Martinez F, Tabar AI. Once daily sublingual immunotherapy without updosing - a new treatment schedule. Int Arch Allergy Immunol 2006; 140; 321-326.
20. D'Ambrosio FP, Ricciardi L, Isola S, Savi E, Parmiani S, Puccinelli P, i wsp. Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol 1996; 24; 146-151.
21. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol 1995; 23: 224-230.
22. Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S, i wsp. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104: 964-968.
23. Purello-D'Ambrosio F, Gangemi S, Isola S, La Motta N, Puccinelli P, Parmiani S, i wsp. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999; 54: 968-973.
24. Sambugaro R, Puccinelli P, Burastero SE, Di Rienzo V. The efficacy of sublingual immunotherapy for respiratory allergy is not affected by different dosage regimens in the induction phase. Allergol Immunopathol 2003; 31: 329-337.
25. Rossi RE, Moasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005; 18: 277-285.
26. Gammeri E, Arena A, D'Anneo R, La Grutta S. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol 2005; 33: 221-223.
27. Tripodi S, Di Rienzo Businco A, Benincori N, Scala G, Pigitore G. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children.Int Arch Allergy Immunol. 2006; 139: 149-152.
28. Madonini E, Agostinis F, Barra R, Berra A, Donadio D, Pappacoda A, i wsp. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 2003; 16: 73-79.
29. Marogna M, Massolo A. Sublingual immunotherapy in the context of a clinical practice improvement program in the allergological setting: results of a long-term observational study. Allergol Immunol 2003; 35: 133-140.
30. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, i wsp. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinocojunctivitis. J Allergy Clin Immunol 2004; 114: 851-857.
31. Mastrandrea F, Serio G, Minelli M, Minardi A, Scarcia G, Coradduzza G, i wsp. Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergol Immunopathol 2000; 28: 54-62.
32. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, i wsp. Sublingual-swallow immunotherapy in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999; 54: 249-260.
33. Ciprandi G, Cirillo I, Fenoglio D, Marseglia G, Tosca MA. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol 2006; 6: 1370-1373.
34. Di Rienzo V, Marcucci F, Puccinelli P, Frati F, Sensi L, Canonica GW, i wsp. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003; 33: 206-210.
35. Gomez Vera J, Flores Sandoval G, Orea Solano M, Lopez Tiro J, Jimenez Saab N. Safety and efficacy of specific sublingual immunotherapy in patients with asthma and allergy to Dermatophagoides pteronyssinus. Rev Alerg Mex 2005; 52: 231-236.
36. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005; 115: 1184-1188.
37. Niu CK, Chen WY, Huang JL, Lue KH, Wang JW. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006; 100: 1374-1383.
38. Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32: 49-55.
39. Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17: 408-415.
40. Rodriguez Santos O. Sublingual immunotherapy with allergenic extract of Dermatophagoides pteronyssinus in asthmatic children. Rev Alerg Mex 2004; 51: 177-180.
41. Pajno GB, Peroni DG, Vita D, Caminiti L, Parmiani S, Barberio G. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled study. Allergy 2004; 59; 883-887.
42. Horak F, Stuber P, Berger UE, Marks B, Toth J, Jager S. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol 1998; 8: 165-171.
43. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986; 16: 483-491.
44. Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual immunotherapy in Cupressaceae arizonica. A double blind study. Allergol Immunopathol 2001; 29: 238-244.
45. Cirla AM, Cirla PE, Parmiani S, Pecora S. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of Grass pollen injective treatmennt In bisensitized individuals. A case-referent, two-year controlled study. Allergol. Immunopathol. 2003; 31: 31-43.
46. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol 1990; 18: 277-284.
47. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a doble-blind study. J Investig Allergol Clin Immunol 1995; 5; 25-30.
48. Valle C, Bazzi S, Berra D, Sillano V, Puccinelli P, Parmiani S. Effects of sublingual ammunotherapy in patients sensitized to Ambrosia. An open controlled study. Allergol Immunopathol 2000; 28: 311-317.
49. Voltolini S, Modena P, Minale P, Bignardi D, Troise C, Puccinelli P, i wsp. Sublingual immunotherapy In tree pollen allergy. Doble-blind, placebo controlled study with a biologically standardized exratct ot three pollens (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol 2001; 29: 103-110.
50. Marcucci F, Sensi L, Frati F, Bernardini R, Novembre E, Barbato A, i wsp. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy 2003; 58; 657-662.
51. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004; 59; 1205-1210.
52. Gozalo F, Martin S, Rico, Alvarez E, Cortes C. Clinical efficacy and tolerance of two years Lolium perenne sublingual immunotherapy. Allergol Immunopathol 1997; 25: 219-227.
53. Mortemousque B, Bertel F, De Casamavor J, Verin P, Colin J. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2003; 33; 464-469.
54. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004; 114: 831-837.
55. Buffe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehihar K, Hoiland-Letz T, i wsp. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004; 59: 498-504.
56. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs 2003; 5: 777-781.
57. Sanchez Palacios A, Schamann F, Garcia JA. Sublingual immunotherapy with cat epithelial extract. Personal experience. Allergol Immunopathol 2001; 29: 60-65.
58. Bordignon V, Parmiani S. Variation of the skin end-point in patients treated with sublingual specific immunotherapy. J Investig Allergol Clin Immunol 2003; 13: 170-176.
59. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003; 33: 1641-1647.
60. Tonnel AB, Scherpereei A, Douay B, Mellin B, Leprince D, Goldstein N, i wsp. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004; 59: 482-484.
61. Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, i wsp. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production.Clin Exp Allergy 2006; 36: 261-272.
62. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000; 55: 842-849.
63. Bowen T, Greenbaum J, Charbonneau Y, Hebert J, Filderman R, Sussman G, i wsp. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004; 93: 425-430.
64. Dehlink E, Eiwegger T, Gerstmayr M, Kampl E, Bohle B, Chen KW, i wsp. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006; 36: 32-39.
65. Feliziani V, Marfisi RM, Parmiani S. Rush immunotherapy with administration of grass alergen extract. Allergol Immunopathol 1993; 21: 173-178.
66. Andre C, Perrin-Favolle M, Grosclaude M, Couturier P. A double-blind placebo-controlled evalution of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003; 131: 111-115.
67. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized contolled study. J Allergy Clin Immunol 2005; 115: 1184-1188.
68. Marcucci F, Sensi L, Frati F, Senna GE, Canonica GW, Parmiani S, i wsp. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 2001; 56: 1091-1095.
69. Grosclaude M, Bouillot P, Alt R, Levnadier F, Scheinmann P, Rufin P, i wsp. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 2002; 129: 248-253.
70. Reich M, Zwacka G, Markert UR. Nonspecific plasma proteins during sublingual immunotherapy. Chem Immunol Allergy 2003; 82: 99-108.